HPV Topical - MACRO HRD

Therapeutic prevention for regions vaccines and screening do not fully reach.

HPV Topical (MACR - 002) is organized around local delivery at the cervicovaginal site, where HPV exposure and early disease processes occur.

HPV is a non-enveloped virus with a protein capsid rather than a lipid envelope, so this program is not based on AH-D envelope-disruption logic.

A preventable cancer still causing major global mortality.

The HPV page frames cervical cancer as a preventable cancer that still causes major global mortality. HPV is responsible for most cervical cancer cases, while vaccine coverage remains lowest in many of the regions where disease burden is highest.

>95%Of cervical cancers are caused by HPV.

340KWomen die from cervical cancer annually worldwide.

85%Of deaths occur in low- and middle-income settings.

<25%Vaccine coverage remains below this level in many high-burden regions.

Vaccination changed prevention, but it does not help every exposed patient.

Human papillomavirus causes more than 95% of cervical cancers. Prophylactic vaccines can protect against infection, but global coverage is uneven.

Vaccines also do not help women who have already been exposed to HPV. The program identifies a need for a therapeutic approach that can target persistent infection and early dysplasia before progression to advanced cervical disease.

This need is especially urgent in regions where cervical cancer mortality is highest and access to screening or vaccination is limited.

Topical mucosal delivery and epithelial localization.

The HPV topical program is organized around local mucosal performance and disease-specific validation. Antibody or multi-specific targeting concepts may be explored for HPV-positive cells or dysplastic tissue environments where supported by future data.

Topical / Mucosal Delivery

Local Mucosal Retention

Topical gel or spray formats are explored for residence time at the cervicovaginal site, where HPV exposure and early disease processes occur.

Epithelial Targeting

Epithelial Penetration and Local Delivery

The program focuses on delivery into or across epithelial environments, with attention to infected or dysplastic cells and local tissue barriers.

Program Evidence

HPV-Specific Mechanism Work

Evidence gates remain HPV-specific because the virus is non-enveloped.

Exploratory prevention strategy for exposure and persistent infection settings.

The HPV program is designed to expand the potential addressable population beyond people who can benefit from prophylactic vaccination alone.

01 Intent

Reducing Local Establishment Risk

The program explores whether local delivery and mucosal retention can help address new HPV exposure at the cervicovaginal site.

02 Intent

Persistent Infection Context

The program also explores disease-modifying strategies for persistent infection and early dysplasia, pending HPV-specific evidence.

Designed for high-burden settings where infrastructure is the constraint.

The HPV program is intended for high-burden settings where conventional vaccine cold-chain systems and screening infrastructure may be limited.

Academic and regional references are presented as scientific or deployment context, with formal collaborations disclosed only when approved for public communication.

Mucosal formulation concepts for local HPV contexts.

Functional peptide and formulation concepts may support local delivery, tissue interaction, or biological modulation in the mucosal environment.

Local tissue interaction

Peptide concepts may be explored for mucosal retention, epithelial interaction, local barrier effects, or biological modulation.

Mucosal residence and uptake

Lipid nanoparticle formulations may be explored for route-specific exposure, mucosal residence time, epithelial uptake, and local tolerability.

Low-resource deployment needs

Formulation concepts may consider storage, handling, and deployment constraints in high-burden settings.

Population-relevant research planning

Future study planning is oriented around populations most affected by HPV-related cervical cancer, with development steps guided by approved partnerships, ethics review, and HPV-specific evidence.

Mucosal-site delivery, exploratory scope, formulation practicality, and population-relevant planning.

The program capabilities are organized around practical delivery, therapeutic and preventive scope, logistics independence, and cohort design for the populations most affected by cervical cancer.

Mucosal-Site Delivery

Topical gel and spray formulations are designed for the cervicovaginal site of HPV transmission, removing the need for systemic injection.

Exploratory Therapeutic + Preventive Scope

The program explores use contexts beyond prophylactic vaccine coverage, including new exposure and persistent infection settings, subject to HPV-specific validation.

Cold-Chain Independence

The formulation is designed for ambient or mildly refrigerated stability, supporting deployment where cold-chain systems may be limited.

Population-Relevant Planning

Future human-study context will be communicated in line with approved partnerships, ethics review, regulatory planning, and public disclosure readiness.

Connected capabilities supporting HPV topical exploration.

The HPV topical program connects topical formulation, local targeting concepts, and evidence planning into an exploratory mucosal program architecture.

Exploratory HPV Topical Program